Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
bioAffinity Technologies, Inc. ( (BIAF) ) has provided an announcement.
On August 12, 2025, bioAffinity Technologies appointed Roberto Rios and John J. Oppenheimer to its Board of Directors, enhancing the company’s financial and clinical expertise. The appointments are part of a strategic move to bolster the company’s growth and development in diagnostics for lung diseases, following Gary Rubin’s resignation from the board.
The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Underperform.
The overall stock score is low due to significant financial challenges and weak technical indicators. While recent corporate events show potential for improvement, the company’s financial instability and negative valuation metrics are major concerns.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics for early detection of lung cancer and other diseases. Its primary product, CyPath® Lung, is a noninvasive test marketed as a Laboratory Developed Test (LDT) by its subsidiary, Precision Pathology Laboratory Services.
Average Trading Volume: 7,055,797
Technical Sentiment Signal: Sell
Current Market Cap: $6.64M
Learn more about BIAF stock on TipRanks’ Stock Analysis page.